Not provided
Not provided
Not provided
Not provided
Not provided
Safety concerns
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Edwards Lifesciences | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the efficacy and safety of implanting an Edwards Sapien XT Valve into the vena cava inferior (VCI; between right atrium and the hepatic vein) on clinical variables, exercise tolerance and well being in patients with severe tricuspid regurgitation and signs of right heart failure.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | Experimental | Transfemoral implantation of an Edwards Sapien XT Valve into the vena cava inferior (VCI). For better stability and for downsizing of the VCI diameter the valve will be implanted after preparation of a landing zone. This includes implantation of one or two self expandable stents into the VCI prior to the final deployment of the valve. |
|
| Group B | No Intervention | Control group (no surgery) with optimal medical treatment. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Edwards Sapien XT Valve | Device | The device will be implanted in the present study to prevent abdominal venous congestion and to improve the function of the tricuspid valve which is located in the low pressure system in the right heart. |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum relative VO2 uptake | we consider the difference of means in maximum relative VO2 uptake at 3 months compared to control group. | at 3 month |
| Measure | Description | Time Frame |
|---|---|---|
| NYHA class | day 30 and month 3 | |
| ejection fraction (EF) | day 30 and month 3 | |
| right ventricular (RV) diameter |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Charite Universitaetsmedizin, Medizinische Klinik für Kardiologie und Angiologie | Berlin | 10117 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39026154 | Derived | Mattig I, Hewing B, Knebel F, Meisel C, Ludwig A, Konietschke F, Stangl V, Stangl K, Laule M, Dreger H. Effect of inferior caval valve implantation on circulating immune cells and inflammatory mediators in severe tricuspid regurgitation. BMC Cardiovasc Disord. 2024 Jul 18;24(1):373. doi: 10.1186/s12872-024-04044-1. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| day 30 and month 3 |
| right atrial (RA) diameter | day 30 and month 3 |
| hepatic vein diameter | day 30 and month 3 |
| N-terminal pro Brain Natriuretic Peptide (NT-proBNP) | day 30 and month 3 |
| tricuspid regurgitation jet velocity time integral (as assessed by Doppler echocardiography) | day 30 and month 3 |
| aerobic threshold (assessed by spiroergometry) | day 30 and month 3 |
| ventilation efficiency (as assessed by the VE / VCO2 slope in spiroergometry) | day 30 and month 3 |
| Unscheduled rehospitalization | day 30 and month 3 |
| Dyspnoea VAS | day 30 and month 3 |
| Minnesota Living with Heart Failure Questionnaire | day 30 and month 3 |
| 6-minutes walk test | day 30 and month 3 |
| ID | Term |
|---|---|
| D014262 | Tricuspid Valve Insufficiency |
| ID | Term |
|---|---|
| D006349 | Heart Valve Diseases |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided